Pacios Olga, Blasco Lucia, Bleriot Inès, Fernandez-Garcia Laura, González Bardanca Mónica, Ambroa Antón, López María, Bou German, Tomás Maria
Microbiology Department-Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), 15009 A Coruña, Spain.
Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) of Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), 28003 Madrid, Spain.
Antibiotics (Basel). 2020 Feb 6;9(2):65. doi: 10.3390/antibiotics9020065.
Antibiotic failure is one of the most worrying health problems worldwide. We are currently facing an international crisis with several problematic facets: new antibiotics are no longer being discovered, resistance mechanisms are occurring in almost all clinical isolates of bacteria, and recurrent infections caused by persistent bacteria are hampering the successful treatment of infections. In this context, new anti-infectious strategies against multidrug-resistant (MDR) and persistent bacteria, as well as the rescue of Food and Drug Administration (FDA)-approved compounds (drug repurposing), are being explored. Among the highlighted new anti-infectious strategies, in this review, we focus on antimicrobial peptides, anti-virulence compounds, phage therapy, and new molecules. As drugs that are being repurposed, we highlight anti-inflammatory compounds, anti-psychotics, anti-helminthics, anti-cancerous drugs, and statins.
抗生素治疗失败是全球最令人担忧的健康问题之一。我们目前正面临一场具有多个问题层面的国际危机:新抗生素不再被发现,几乎所有临床分离细菌中都出现了耐药机制,由持续性细菌引起的反复感染阻碍了感染的成功治疗。在此背景下,针对多重耐药(MDR)和持续性细菌的新抗感染策略以及美国食品药品监督管理局(FDA)批准化合物的拯救(药物重新利用)正在被探索。在突出的新抗感染策略中,在本综述中,我们重点关注抗菌肽、抗毒力化合物、噬菌体疗法和新分子。作为正在被重新利用的药物,我们重点介绍抗炎化合物、抗精神病药物、抗蠕虫药物、抗癌药物和他汀类药物。